

# **Modafinil and Stimulant Alternatives in Japan — A Regulatory and Comparative Analysis**

### **Executive Summary**

This report provides a comprehensive analysis of the regulatory, clinical, and competitive landscape for Modafinil and its alternatives in Japan. The analysis reveals a market characterized by a unique regulatory paradox, stringent importation controls, and a dynamic shift toward novel therapeutic mechanisms.

Modafinil, marketed in Japan as Modiodal, holds a complex position. It is classified under the *Narcotics and Psychotropics Control Law* as a **Schedule I Psychotropic Drug**, the most restrictive category, subjecting it to rigorous controls on prescribing, dispensing, and personal importation. This classification reflects Japan's profoundly risk-averse approach to substances with any perceived potential for abuse. Paradoxically, clinical guidelines simultaneously recognize Modafinil as a **first-line treatment for narcolepsy**, preferring it over older stimulants like methylphenidate due to a more favorable safety and dependency profile.

The regulatory framework governing these substances is a dual-key system. The *Act on Securing Quality, Efficacy and Safety of Products (PMD Act)* governs the fundamental approval of all medical products based on scientific evidence of safety and efficacy, a process overseen by the Pharmaceuticals and Medical Devices Agency (PMDA). In parallel, the *Narcotics and Psychotropics Control Law*, enforced by the Ministry of Health, Labour and Welfare's (MHLW) Narcotics Control Department (NCD), imposes a separate layer of strict controls on substances deemed to have abuse potential. Success in the Japanese market requires navigating both of these independent regulatory streams.

For individuals, the personal importation of controlled medications like Modafinil is a complex, multi-tiered process. Rules are not based on a single metric but on a combination of drug classification, dosage form, and specific quantity limits (e.g., a 6-gram threshold for Modafinil), which can require either no documentation, a doctor's certificate, or a full *Yunyu Kakunin-sho* (Import Confirmation certificate).

The competitive landscape is evolving from traditional CNS stimulants toward more targeted, mechanistically diverse alternatives. While methylphenidate's use is declining, emerging non-stimulant therapies like the histamine H3 receptor antagonist Pitolisant and disease-modifying orexin agonists represent the future of the market. The recent reform of cannabis regulations, shifting from a "parts-based" to a "component-based" (THC content) system, signals a broader move by Japanese regulators toward quantitative, science-based risk assessment, creating a significant precedent for future novel drug approvals.

This report concludes that while Japan's regulatory environment for psychostimulants remains one of the world's most stringent, it is predictable and navigable. Success for both individuals and pharmaceutical companies hinges on a meticulous understanding of and adherence to this complex legal framework and an appreciation for a market that increasingly values novel mechanisms and superior safety profiles over incremental improvements in stimulation.

## **1\. The Regulatory Profile of Modafinil (Modiodal) in Japan**

Modafinil occupies a unique and often misunderstood position within Japan's pharmaceutical landscape. It is simultaneously a clinically preferred, first-line therapy for specific sleep disorders and a highly controlled substance subject to the nation's most stringent regulations for psychotropic drugs. Understanding this dual identity is fundamental to navigating its use, importation, and market dynamics.

### **1.1. A Controlled Substance: Classification as a Schedule I Psychotropic**

The legal status of Modafinil in Japan is unequivocally defined by its classification under the nation's primary law for controlling substances with abuse potential.

#### **Legal Designation**

Modafinil (モダフィニル) is classified as a **Schedule I Psychotropic Drug (第一種向精神薬)** under Japan's *Narcotics and Psychotropics Control Law*.1 This is the most restrictive category for psychotropic substances, placing it under a regulatory regime just below that of narcotics. The official designation was made on September 8, 2006, after the Ministry of Health, Labour and Welfare (MHLW) conducted a one-month public comment period, indicating a deliberate and formal process leading to its classification.1 The substance's chemical name, 2-\[(diphenylmethyl)sulfinyl\]acetamide, and its salts are covered by this designation.2 This classification is further corroborated by its entry (D01832) in the Kyoto Encyclopedia of Genes and Genomes (KEGG) Drug database, which explicitly lists it as a psychotropic designated by the relevant government ordinance.4

#### **Implications of Classification**

Placement in Schedule I carries profound consequences that shape every aspect of Modafinil's lifecycle in Japan. These regulations are designed to prevent diversion and misuse, reflecting a deep-seated institutional cautiousness.

* **Strict Handling and Severe Penalties:** The classification subjects Modafinil to the *Narcotics and Psychotropics Control Law*, which strictly prohibits unauthorized import, export, manufacturing, dispensing, and possession. Violations of these prohibitions carry severe criminal penalties, including lengthy prison sentences and substantial fines.2 For instance, illicit manufacturing or import can result in up to five years of imprisonment, which increases to seven years and a fine of up to JPY 2 million if done for profit.2  
* **Registered Prescribers and Pharmacies:** A critical barrier to access is the requirement for specialized registration. The package insert for Modiodal, the brand name for Modafinil in Japan, carries a stark warning that the drug may only be prescribed by physicians and dispensed by pharmacists who are registered under a specific MHLW program. These healthcare professionals must be fully educated on the drug's proper use, safety profile, and risks.3 This system effectively creates a closed loop of distribution, ensuring that only specialists with demonstrated knowledge of sleep disorders can manage patient treatment.  
* **Record-Keeping and Oversight:** As a Schedule I psychotropic, all transactions involving Modafinil, including receipt, dispensing, and disposal, must be meticulously recorded and are subject to audit by regulatory authorities. This creates a significant administrative burden for the hospitals and pharmacies authorized to handle the drug.2

This stringent legal framework establishes Modafinil not as a general medication but as a specialized therapeutic agent whose use is tightly policed from manufacture to patient administration.

### **1.2. Approved Indications and Clinical Guidelines**

Despite its restrictive legal status, Modafinil is a cornerstone of modern therapy for certain sleep-wake disorders in Japan, valued for its efficacy and comparatively favorable safety profile.

#### **Approved Uses**

Modafinil, marketed under the brand name Modiodal by Alfresa Pharma and Mitsubishi Tanabe Pharma, is officially approved in Japan to improve excessive daytime sleepiness (EDS) associated with the following conditions 3:

1. **Narcolepsy (ナルコレプシー)** 1  
2. **Idiopathic Hypersomnia (特発性過眠症)** 6  
3. **Obstructive Sleep Apnea Syndrome (閉塞性睡眠時無呼吸症候群)**.6 It is crucial to note that for OSAS, Modafinil is indicated only as an adjunctive therapy for patients with residual EDS despite at least three months of primary treatment for airway obstruction, such as Continuous Positive Airway Pressure (CPAP) therapy.3 The drug is not a treatment for the underlying airway obstruction itself.8

#### **Clinical Positioning and Guidelines**

Japanese clinical guidelines for the treatment of narcolepsy position Modafinil as a **first-line treatment for EDS**.9 This is a critical distinction. While older stimulants like methylphenidate are available, Modafinil is clinically preferred due to its lower risk of dependency and abuse.9 This preference highlights the regulatory paradox: the medical community values Modafinil for its relative safety compared to other stimulants, yet the legal framework places it in the highest-risk category for psychotropics. This reflects a system that separates clinical utility from a blanket assessment of abuse potential. A 2022 study analyzing prescription trends in Japan from 2010 to 2019 confirmed this shift, showing that while methylphenidate prescriptions declined over the decade, Modafinil prescriptions steadily increased, becoming the most commonly prescribed agent for narcolepsy.12

#### **Dosage and Administration**

The standard dosage regimen for adults is 200 mg administered orally once a day in the morning. The dose can be adjusted based on age and symptoms, but the maximum daily dose is capped at 300 mg.3 The prescribing information explicitly warns against evening administration due to the drug's wakefulness-promoting effects, which can cause insomnia.3

### **1.3. The Gauntlet of Personal Importation**

The personal importation of Modafinil into Japan is one of the most complex areas of pharmaceutical regulation for individuals, governed by a multi-layered system of rules that can be difficult to navigate.

#### **General Rules for Psychotropics**

The overarching principle is that personal importation of psychotropic drugs is heavily restricted. It is fundamentally prohibited unless the individual is carrying the medication for their own documented medical use.16 This means that having someone else carry the medication or having it sent by international mail is illegal.18 The traveler must personally carry their own supply.

#### **A Multi-Tiered System of Scrutiny**

Unlike general prescription drugs, which have a straightforward one-month supply limit before requiring an import certificate, psychotropics are subject to a more nuanced, tiered system of control based on the specific substance and quantity.

1. **The Quantity Threshold:** The Narcotics Control Department (NCD) maintains a specific table of quantity limits for psychotropic substances. For Modafinil, this limit is **6 grams**.19 A traveler carrying a total amount of Modafinil equal to or less than 6g does not require special permission under the  
   *Narcotics and Psychotropics Control Law*.20  
2. **Exceeding the Threshold (Doctor's Certificate Required):** If a traveler intends to carry more than 6g of Modafinil, they are required to carry a certificate from their prescribing physician. This document must prove that the medication is essential for their treatment and should detail the patient's name, the disease being treated, and the specific names and quantities of the psychotropic drugs.18  
3. **Exceeding the One-Month Supply (Import Confirmation Required):** Independently of the 6g threshold, there is a general rule that applies to all prescription drugs, including psychotropics. If the amount of medication to be imported exceeds a one-month supply, the traveler must apply for and obtain a **Yunyu Kakunin-sho (輸入確認証)**, or Import Confirmation certificate, *before* traveling to Japan.22 This document, formerly known as a  
   *Yakkan Shoumei*, is issued by the Regional Bureau of Health and Welfare corresponding to the traveler's airport of arrival.26

This creates a complex decision matrix. A traveler with a 15-day supply of 200mg Modafinil tablets (total 3g) would need no special paperwork. A traveler with a 25-day supply (total 5g) would still be under the 6g limit and would not need a doctor's note under the NCD rules, but would also not need a *Yunyu Kakunin-sho* as it is less than a one-month supply. However, a traveler with a 25-day supply of 300mg tablets (total 7.5g) would exceed the 6g limit and thus require a doctor's certificate. Finally, a traveler with a 45-day supply of 200mg tablets (total 9g) would exceed both the 6g limit and the one-month supply rule, thus requiring both a doctor's certificate *and* a *Yunyu Kakunin-sho*. This intricate interplay of rules makes compliance exceptionally challenging without expert guidance.

## **2\. The Japanese Regulatory Framework for Psychostimulants and Sleep Disorder Medications**

The complex status of Modafinil is not an anomaly but a direct result of Japan's multi-layered and highly risk-averse regulatory system for pharmaceuticals. This framework is built upon two distinct legal pillars, enforced by separate but coordinated government agencies, which together create a formidable barrier to market entry and a challenging environment for personal importation.

### **2.1. The Dual Pillars of Pharmaceutical Control**

Market access and control of any medical product in Japan are governed by two principal laws that operate in parallel. A drug must satisfy the requirements of both to be legally marketed and used.

#### ***Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act)***

This is the foundational legislation for all medical products in Japan, often abbreviated as the PMD Act or *Yakki-hō* (薬機法).28 First enacted in 1960 as the Pharmaceutical Affairs Law, it was significantly revised and renamed in 2014\.28 The PMD Act's purpose is to ensure the quality, efficacy, and safety of all pharmaceuticals, quasi-drugs, cosmetics, and medical devices.30 It governs the entire product lifecycle, including:

* **Clinical Trials:** Setting the standards for trials conducted in Japan.  
* **Marketing Approval (承認, *shōnin*):** The formal approval required to market a new drug, granted after a rigorous review of safety and efficacy data.33  
* **Manufacturing Licenses (許可, *kyoka*):** Licenses specific to the facilities where drugs are produced.33  
* **Labeling and Advertising:** Strict rules on what information must be displayed and prohibiting false or exaggerated claims.30  
* **Post-Marketing Surveillance:** Requirements for ongoing safety monitoring after a drug is on the market.29

Under the PMD Act, drugs are broadly classified based on their risk profile and how they are supplied, such as "prescription drugs," "guidance-mandatory drugs," and "non-prescription drugs".34 A "prescription drug" is one designated by the MHLW as requiring the prescription of a physician, dentist, or veterinarian for use.34

#### ***Narcotics and Psychotropics Control Law***

This law operates as a specialized overlay on top of the PMD Act. Its sole focus is to control substances that have a potential for abuse, dependency, and harm to public health.35 A drug approved under the PMD Act that contains a substance designated under this law is subject to a second, more stringent layer of regulation.

The law establishes several categories of controlled substances, each with its own set of rules for handling, prescribing, and importation:

* **Narcotics (麻薬, *mayaku*):** The most strictly controlled category, including substances like morphine and cocaine. These are defined as drugs with a high potential for abuse and severe harm.34  
* **Psychotropics (向精神薬, *kōseishin'yaku*):** Substances that affect the central nervous system and are habit-forming but are considered to pose a less severe risk than narcotics.34 This category is further divided into three schedules based on risk:  
  * **Schedule I:** Highest risk within the psychotropic class (e.g., Modafinil, Methylphenidate).1  
  * **Schedule II:** Intermediate risk (e.g., Pentazocine, Flunitrazepam).38  
  * **Schedule III:** Lowest risk (e.g., Diazepam, Triazolam).38  
* **Stimulants (覚醒剤, *kakuseizai*):** A separate category under the *Stimulants Control Law* that includes amphetamine and methamphetamine. Their importation is strictly prohibited, even for medical use.16

This dual-key system means that a drug like Modafinil must first prove its safety and efficacy to the PMDA under the PMD Act, and then, because of its psychoactive properties, it must also comply with the strict handling and control measures of the *Narcotics and Psychotropics Control Law*.

### **2.2. The Gatekeepers: Roles of MHLW, PMDA, and NCD**

Three key governmental bodies enforce this dual regulatory framework.

* **Ministry of Health, Labour and Welfare (MHLW):** As the cabinet-level ministry, the MHLW is the ultimate regulatory authority. It sets overarching pharmaceutical policy, issues the final marketing approvals (*shōnin*) based on PMDA recommendations, and holds the power to designate substances as narcotics or psychotropics, thereby triggering the second layer of control.20  
* **Pharmaceuticals and Medical Devices Agency (PMDA):** The PMDA is the scientific workhorse of the regulatory system. It is an independent administrative institution that works in concert with the MHLW. Its primary function is to conduct the rigorous scientific and technical reviews of new drug applications, clinical trial data, and post-marketing safety information to ensure products meet the standards of the PMD Act.43  
* **Narcotics Control Department (NCD):** The NCD is a specialized law enforcement and administrative division within the MHLW's regional bureaus. Its mandate is the enforcement of the *Narcotics and Psychotropics Control Law*. The NCD is the agency that issues import/export permits for controlled substances, conducts inspections of facilities handling these drugs, and investigates illicit activities. Individuals seeking to import a personal supply of a controlled medication like Modafinil or Methylphenidate must apply to and receive permission from the NCD office that has jurisdiction over their port of entry.27

### **2.3. A Case Study in Regulatory Evolution: The Path of Cannabidiol (CBD)**

The recent evolution of CBD regulation in Japan provides a powerful case study of how this system can adapt, albeit slowly, in the face of scientific evidence and medical necessity. It signals a potential shift from categorical prohibitions to more nuanced, quantitative risk assessment.

#### **The Old Paradigm: "Parts-Based" Regulation**

Until late 2024, the legality of CBD products was determined not by their chemical composition but by the part of the cannabis plant from which they were derived. The *Cannabis Control Act* specifically excluded mature stalks and seeds from its definition of "cannabis".44 Therefore, CBD products were legal only if importers could prove they were extracted exclusively from these parts. Products derived from leaves or flowers were illegal, regardless of their THC content.47 This "parts-based" or "部位規制" (

*bui kisei*) approach was unscientific and created significant ambiguity, as proving the origin of a highly processed oil was practically difficult.

#### **The New Paradigm: "Component-Based" Regulation**

A landmark amendment to the *Cannabis Control Act* and the *Narcotics and Psychotropics Control Law*, which took full effect on December 12, 2024, fundamentally changed this paradigm.48 The new framework abandons the "parts-based" rule in favor of a "component-based" or "成分規制" (

*seibun kisei*) approach, focusing squarely on the presence of the primary psychoactive component, Δ9-tetrahydrocannabinol (THC).

Under the new law, any product—regardless of its origin—that contains THC above a specified residue limit is now classified as a "narcotic" and is illegal. The MHLW has established extremely strict, quantifiable limits 54:

* **Oils, Powders, and Raw Materials:** 10 ppm (10 mg/kg or 0.001%)  
* **Beverages:** 0.1 ppm (0.1 mg/kg or 0.00001%)  
* **Other Foods (e.g., Edibles):** 1 ppm (1 mg/kg or 0.0001%)

#### **Drivers of Regulatory Change**

This significant regulatory evolution was propelled by two primary forces:

1. **Medical Necessity:** The most powerful driver was the need to approve cannabis-derived pharmaceuticals, specifically Epidiolex (a CBD-based drug), for treating severe pediatric epilepsy. Under the old law, its approval was impossible. The new framework creates a legal pathway for such medicines to be approved and used under the strict controls of the *Narcotics and Psychotropics Control Law*.49  
2. **Rationalizing the Market:** The growing popularity of CBD products and the ambiguity of the old law created an untenable situation. The new, science-based standard provides clear, measurable rules for the industry and enhances consumer safety by focusing on the actual psychoactive component.51

This shift from a categorical prohibition based on plant anatomy to a quantitative risk assessment based on chemical content is a critical development. It demonstrates that Japan's regulatory system, while inherently conservative, is capable of evolving. It suggests that for future novel compounds with potential psychoactive effects, a regulatory pathway based on robust scientific data demonstrating a low quantitative risk of abuse may be possible, especially when linked to a clear and compelling unmet medical need. This precedent is a vital piece of strategic intelligence for any pharmaceutical company operating in the CNS space.

## **3\. A Comparative Analysis of Wakefulness-Promoting Agents**

Modafinil does not exist in a vacuum. It competes with both older stimulants and a new wave of innovative therapies in the Japanese market for sleep-wake disorders. A comparative analysis of these agents reveals a clear trajectory in clinical preference and drug development, moving away from broad stimulation and toward targeted, safer mechanisms of action.

### **3.1. The Predecessor: Methylphenidate (Ritalin/Concerta)**

Methylphenidate was the historical mainstay for treating disorders of excessive sleepiness and remains a key treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in Japan.

#### **Regulatory Status**

Methylphenidate shares a similar, highly restrictive regulatory status with Modafinil. It is classified as a **Schedule I Psychotropic** under the *Narcotics and Psychotropics Control Law*, subjecting it to the strictest controls on handling, prescribing, and record-keeping.38 The personal importation of methylphenidate is tightly policed by the Narcotics Control Department. A special certificate from the NCD is required to bring it into the country.18 The quantity limit that triggers the need for a doctor's certificate for personal import is

**2.16 grams** of the active ingredient.19

#### **Clinical Use and Market Trend**

While effective for narcolepsy and ADHD, methylphenidate's use in narcolepsy has been steadily declining in Japan. A comprehensive study of a Japanese health insurance claims database from 2010 to 2019 provides clear evidence of this trend. In 2010, methylphenidate was a commonly prescribed agent for narcolepsy, used by 27.3–38.9% of patients. By 2019, this figure had dropped to 15.6–17.1%. Over the same period, Modafinil prescriptions surged from 17.5–45.5% to 43.8–45.8%, establishing it as the dominant first-line therapy.12

#### **Comparison to Modafinil**

The primary reason for this clinical shift is the difference in their perceived safety and dependency profiles. Although both are effective CNS stimulants, methylphenidate is associated with a higher potential for dependence and abuse.11 Japanese clinical guidelines and prescribing practices reflect a clear preference for Modafinil as a safer first-line option for narcolepsy, reserving methylphenidate for cases where Modafinil is ineffective or not tolerated.9 This trend underscores a key principle in the Japanese market: even within a class of highly controlled drugs, a superior safety profile is a powerful driver of clinical adoption.

### **3.2. The New Wave: Emerging Non-Stimulant Therapies**

The future of the wakefulness market in Japan is being shaped by innovative therapies that move beyond the traditional stimulant model. Two classes of drugs, in particular, represent the next frontier in treatment.

#### **Pitolisant (Development Code: BF2.649)**

* **Mechanism of Action:** Pitolisant represents a completely different approach to promoting wakefulness. It is a novel, non-stimulant agent that functions as a selective **histamine H3 receptor antagonist/inverse agonist**. By blocking these autoreceptors on presynaptic histamine neurons, it enhances the release of histamine in the brain, a key neurotransmitter in maintaining arousal.63  
* **Development Status in Japan:** In a major development, Aculys Pharma announced in January 2025 the successful completion of a **Phase III clinical trial of Pitolisant in Japan**. The study evaluated its use in OSAS patients who experience residual EDS despite optimal CPAP therapy. The trial met its primary efficacy endpoint, showing a statistically significant improvement in sleepiness scores compared to placebo (p=0.007). The safety and tolerability profile was consistent with overseas studies, with no serious adverse events reported.63  
* **Market Significance:** The success of this trial is highly significant. Pitolisant is poised to be the first new drug option for this indication in Japan in approximately 15 years, addressing a substantial unmet medical need. Its non-stimulant mechanism could make it an attractive alternative for patients who cannot tolerate or do not wish to take traditional stimulants like Modafinil. Aculys Pharma has stated its intention to submit a New Drug Application (NDA) based on these results, positioning Pitolisant as a major near-term competitor.63

#### **Orexin Agonists (e.g., Takeda's TAK-861)**

* **Mechanism of Action:** Orexin agonists are a revolutionary class of drugs that aim to treat the root cause of narcolepsy type 1 (NT1). NT1 is caused by the autoimmune destruction of neurons in the hypothalamus that produce orexin (also known as hypocretin), a critical neuropeptide for maintaining wakefulness and regulating sleep cycles. Orexin agonists are designed to mimic the action of this missing neuropeptide by directly activating orexin receptors in the brain, thereby restoring the lost wakefulness signals.64  
* **Development Status:** Takeda Pharmaceutical Company, a major Japanese firm, is at the forefront of developing this class. Their research journey highlights both the immense potential and the significant risks. An earlier oral compound, TAK-994, showed remarkable efficacy in early trials but was unfortunately halted due to cases of liver toxicity. This setback underscores the challenges of developing novel CNS drugs. However, Takeda has pivoted to a second-generation compound, **TAK-861**, which is currently in Phase 2 clinical trials for NT1.64  
* **Market Significance:** If successful, orexin agonists represent a true paradigm shift. They move beyond merely managing symptoms (i.e., forcing wakefulness with stimulants) to a more restorative therapy that targets the underlying pathophysiology. By restoring orexin signaling, these drugs have the potential to treat not only EDS but also the full spectrum of NT1 symptoms, including cataplexy, sleep paralysis, and disrupted nighttime sleep. This could render many current symptomatic treatments, including Modafinil and antidepressants, obsolete for this patient population. The deep investment by a company like Takeda signals the transformative potential of this approach.64

### **3.3. Ancillary Treatments: Antidepressants**

While not direct competitors to Modafinil for its primary indication, antidepressants play a crucial complementary role in the management of narcolepsy.

Selective serotonin reuptake inhibitors (SSRIs) like fluvoxamine and paroxetine, serotonin-norepinephrine reuptake inhibitors (SNRIs) like venlafaxine, and older tricyclic antidepressants (TCAs) like clomipramine are prescribed to manage the REM-sleep-related symptoms of narcolepsy. Their primary targets are **cataplexy** (sudden loss of muscle tone triggered by emotion), **hypnagogic hallucinations** (vivid dreams at sleep onset), and **sleep paralysis**. These symptoms are thought to be caused by the intrusion of REM sleep phenomena into wakefulness. By suppressing REM sleep, these antidepressants can effectively control these debilitating symptoms.12 They are often used in combination with wakefulness-promoting agents like Modafinil, which do not treat cataplexy.

### **Table 1: Comparative Profile of Wakefulness-Promoting Agents in Japan**

| Drug Name (Generic/Brand) | Regulatory Status (Japan) | Mechanism of Action | Primary Approved/Targeted Indications (Japan) | Key Advantages | Key Disadvantages / Risks |
| :---- | :---- | :---- | :---- | :---- | :---- |
| **Modafinil** (Modiodal) | Schedule I Psychotropic 1 | Weak dopamine reuptake inhibitor; affects multiple neurotransmitter systems (histamine, GABA) 7 | Narcolepsy, Idiopathic Hypersomnia, adjunctive for OSAS 3 | Established efficacy; lower dependency risk than amphetamines; first-line therapy for narcolepsy 9 | Strict regulatory control; potential for psychiatric side effects; risk of severe skin reactions (e.g., SJS) 8 |
| **Methylphenidate** (Ritalin/Concerta) | Schedule I Psychotropic 38 | Dopamine and norepinephrine reuptake inhibitor (CNS stimulant) 69 | Narcolepsy, ADHD 70 | Strong, rapid-acting wakefulness promotion | Higher potential for dependence and abuse; declining use in narcolepsy; strict import/prescribing rules 11 |
| **Pitolisant** (BF2.649) | Investigational (NDA planned) | Histamine H3 receptor antagonist/inverse agonist (non-stimulant) 63 | OSAS (residual EDS); Narcolepsy (overseas) | Novel non-stimulant mechanism; favorable safety profile in trials; addresses unmet need 63 | Awaiting regulatory approval; long-term safety data in Japan still being established |
| **Orexin Agonists** (TAK-861) | Investigational (Phase 2\) | Orexin-2 receptor agonist; targets underlying pathophysiology of NT1 64 | Narcolepsy Type 1 | Potential to be disease-modifying, treating all core symptoms (EDS, cataplexy); could be a paradigm shift 64 | High-risk development; potential for off-target effects (e.g., liver toxicity seen in previous compound) 64 |

This comparative analysis clearly illustrates the evolution of the therapeutic landscape. The market is moving away from the broad-spectrum stimulation of methylphenidate toward the more nuanced action of Modafinil. The next wave of competition will come not from better stimulants, but from entirely new classes of drugs like Pitolisant and orexin agonists, which offer the promise of targeted modulation of specific neurological pathways with potentially greater efficacy and improved safety. This shift from a "stimulation" paradigm to a "modulation" paradigm is the defining strategic trend in this therapeutic area.

## **4\. Strategic Insights and Future Outlook**

The intricate regulatory landscape and dynamic clinical environment for wakefulness-promoting agents in Japan present both significant challenges and unique opportunities. A clear understanding of the rules is essential for individuals seeking treatment, while a strategic interpretation of market trends is critical for industry stakeholders.

### **4.1. Guidance for Individuals and Prescribers**

For patients and travelers, navigating Japan's pharmaceutical regulations, particularly for controlled substances, requires meticulous preparation and an unwavering commitment to compliance.

#### **Navigating Personal Importation: A Step-by-Step Guide**

The process for legally importing a personal supply of medication can be demystified by following a clear, sequential process.

1. **Step 1: Determine the Drug's Classification.** The first and most critical step is to identify how the medication is classified in Japan. This is not based on its status in one's home country. Use official sources from the MHLW and the NCD to determine if the drug is a general prescription drug, a psychotropic (and which schedule), a narcotic, or a prohibited stimulant.72 For example, Modafinil is a Schedule I Psychotropic, while amphetamines (e.g., Adderall) are strictly prohibited.73  
2. **Step 2: Verify the Quantity Limits.** Once the classification is known, check the specific quantity limits.  
   * For **general prescription drugs**, the limit is a **one-month supply** without needing a *Yunyu Kakunin-sho*.26  
   * For **psychotropics**, consult the NCD's table of specific limits. For Modafinil, the limit is **6 grams**; for Methylphenidate, it is **2.16 grams**.19 Exceeding this gram limit requires a doctor's note, even if the supply is less than one month.  
   * For **injectable drugs** (e.g., pre-filled syringes), the limit is a **one-month supply**, but any amount generally requires a *Yunyu Kakunin-sho* or at least a doctor's certificate.23  
3. **Step 3: Obtain Necessary Documentation in Advance.** If the intended quantity exceeds the permissible limits, action must be taken *before* traveling.  
   * Obtain a detailed **doctor's certificate** if carrying a psychotropic drug over its specified gram limit.18  
   * Apply for and receive a ***Yunyu Kakunin-sho*** if carrying more than a one-month supply of any prescription drug or psychotropic.22 The application is now online and should be submitted to the Regional Bureau of Health and Welfare for the intended airport of arrival at least two to three weeks before departure.26  
4. **Step 4: Carry and Declare Properly.** All medications should be kept in their original, labeled pharmacy containers. Loose pills are not advisable. Carry all medications, prescriptions, and certificates in your carry-on luggage. Be prepared to declare the items at customs and present all documentation upon request.18

#### **Understanding Legal Responsibilities**

It is imperative to understand that Japanese authorities enforce these laws strictly. Ignorance of the regulations is not a valid defense. Attempting to import prohibited substances or quantities exceeding the legal limits without the proper authorization can result in severe consequences, including confiscation of the medication, detention, and arrest.74

### **Table 2: Summary of Personal Medication Importation Rules in Japan**

| Category of Medication | Quantity Limit (without special permission) | Documentation Required (if exceeding limit) | Governing Law / Authority |
| :---- | :---- | :---- | :---- |
| **General Prescription Drugs** (Non-controlled) | 1-month supply 16 | *Yunyu Kakunin-sho* 76 | PMD Act / MHLW |
| **Psychotropic Drugs** (e.g., Modafinil, Diazepam) | Varies by substance (e.g., 6g for Modafinil) 19 | Doctor's Certificate. If supply also \>1 month, a *Yunyu Kakunin-sho* is also needed.18 | Narcotics & Psychotropics Control Law / NCD |
| **Narcotics / Stimulant Raw Materials** (e.g., Methylphenidate, Codeine, Lisdexamfetamine) | Any amount requires permission 18 | Special Import/Export Permit from NCD 18 | Narcotics & Psychotropics Control Law / Stimulants Control Law / NCD |
| **Injectable Drugs** (Pre-filled Syringes/Kits) | 1-month supply 23 | *Yunyu Kakunin-sho* is generally required for any amount.25 | PMD Act / MHLW |
| **Prohibited Stimulants** (e.g., Amphetamine, Methamphetamine) | Zero. Import is strictly prohibited.73 | N/A (Import is illegal) | Stimulants Control Law / NCD |

### **4.2. Analysis for Industry Stakeholders**

For pharmaceutical companies, the Japanese market for CNS drugs presents a high-risk, high-reward environment. The regulatory hurdles are substantial, but the successful commercialization of a novel therapy can be highly lucrative.

#### **Market Access Strategy**

The key to navigating this market is to recognize that the dual-key regulatory system, while stringent, is not arbitrary. The CBD case study is the most important recent precedent, demonstrating that the MHLW is willing to modernize its regulations and adopt a science-based approach when faced with a compelling unmet medical need and robust scientific data.49 This opens the door for innovative companies to engage with regulators on a quantitative risk-assessment basis.

#### **Key Success Factors**

Based on the analysis, several factors are critical for success:

* **A Robust and Comprehensive Data Package:** Efficacy data alone is insufficient. A successful NDA submission for a psychoactive drug must include a comprehensive package of non-clinical and clinical data specifically addressing abuse liability, dependency potential, and long-term safety.  
* **Targeting High Unmet Needs:** The MHLW is more likely to be flexible for drugs that treat serious, well-defined conditions with few effective options, such as narcolepsy or treatment-resistant OSAS. Pursuing broader, "lifestyle" indications like cognitive enhancement would face insurmountable regulatory resistance.  
* **Strategic Local Partnerships:** The path of Modiodal, which was brought to market through a partnership between the originator (Cephalon) and Japanese companies (Nippon Shoji, now Alfresa Pharma), provides a successful template. Local partners bring invaluable expertise in navigating the nuances of the Japanese clinical trial environment, the PMDA review process, and the complex distribution system for controlled substances.77

### **4.3. Future Trajectory**

The Japanese market for wakefulness-promoting agents is at an inflection point, with a clear trajectory away from traditional stimulants and toward novel, targeted therapies.

* **Near-Term Disruption:** The anticipated approval of **Pitolisant** will be the most significant near-term event. As the first new, non-stimulant option in over a decade, it is likely to capture a significant market share, particularly among patients and physicians seeking to avoid the side effects and regulatory burdens of controlled stimulants.63  
* **Long-Term Paradigm Shift:** The ultimate future of narcolepsy treatment lies with disease-modifying therapies like **orexin agonists**. While their development path is fraught with risk, as demonstrated by Takeda's experience, their potential to restore normal neurological function rather than just mask symptoms is a "holy grail" that could completely reshape the treatment landscape, making current symptomatic therapies second-line or obsolete.64  
* **Regulatory Outlook:** The regulatory framework will continue its gradual evolution. The core principles of prioritizing public safety and preventing diversion and abuse will remain unchanged. However, the CBD precedent suggests an increasing willingness to engage with science-based, quantitative arguments. Companies that can provide robust data packages demonstrating a favorable benefit-risk profile, particularly regarding abuse potential, and who target clear unmet medical needs, will be best positioned to succeed in this challenging but rewarding market.

#### **Works cited**

1. モダフィニル \- Wikipedia, accessed July 12, 2025, [https://ja.wikipedia.org/wiki/%E3%83%A2%E3%83%80%E3%83%95%E3%82%A3%E3%83%8B%E3%83%AB](https://ja.wikipedia.org/wiki/%E3%83%A2%E3%83%80%E3%83%95%E3%82%A3%E3%83%8B%E3%83%AB)  
2. モダフィニルの向精神薬指定 \- 栃木県, accessed July 12, 2025, [https://www.pref.tochigi.lg.jp/e07/welfare/iryou/yakuji/modafiniru.html](https://www.pref.tochigi.lg.jp/e07/welfare/iryou/yakuji/modafiniru.html)  
3. 医療用医薬品 : モディオダール, accessed July 12, 2025, [https://www.kegg.jp/medicus-bin/japic\_med?japic\_code=00052776](https://www.kegg.jp/medicus-bin/japic_med?japic_code=00052776)  
4. モダフィニル \- KEGG DRUG, accessed July 12, 2025, [https://www.kegg.jp/entry/dr\_ja:D01832](https://www.kegg.jp/entry/dr_ja:D01832)  
5. 薬局における向精神薬取扱いの手引 \- 厚生労働省, accessed July 12, 2025, [https://www.mhlw.go.jp/bunya/iyakuhin/yakubuturanyou/dl/kouseishinyaku\_02.pdf](https://www.mhlw.go.jp/bunya/iyakuhin/yakubuturanyou/dl/kouseishinyaku_02.pdf)  
6. 個別薬剤情報表示, accessed July 12, 2025, [https://shinryohoshu.mhlw.go.jp/shinryohoshu/yakuzaiMenu/doYakuzaiInfoKobetsu&1179047F1022;jsessionid=087AAB8B1E7C52F1CC7653D326C1BDEB](https://shinryohoshu.mhlw.go.jp/shinryohoshu/yakuzaiMenu/doYakuzaiInfoKobetsu&1179047F1022;jsessionid=087AAB8B1E7C52F1CC7653D326C1BDEB)  
7. Efficacy and Safety of Adjunctive Modafinil Treatment on Residual Excessive Daytime Sleepiness among Nasal Continuous Positive Airway Pressure-Treated Japanese Patients with Obstructive Sleep Apnea Syndrome: A Double-Blind Placebo-Controlled Study \- PubMed Central, accessed July 12, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC3716665/](https://pmc.ncbi.nlm.nih.gov/articles/PMC3716665/)  
8. モディオダール錠 100mg \- 医薬品医療機器情報提供ホームページ, accessed July 12, 2025, [https://www.info.pmda.go.jp/downfiles/ph/GUI/530258\_1179047F1022\_2\_00G.pdf](https://www.info.pmda.go.jp/downfiles/ph/GUI/530258_1179047F1022_2_00G.pdf)  
9. ナルコレプシーの診断・治療ガイドライン項目（目次） \- 日本睡眠学会, accessed July 12, 2025, [https://jssr.jp/files/guideline/narcolepsy.pdf](https://jssr.jp/files/guideline/narcolepsy.pdf)  
10. ナルコレプシーの場合、主にどのような治療をしますか？ \- ユビー, accessed July 12, 2025, [https://ubie.app/byoki\_qa/clinical-questions/jj58-60w092](https://ubie.app/byoki_qa/clinical-questions/jj58-60w092)  
11. ナルコレプシーなど過眠症群で用いられる薬 \- 十三メンタルクリニック, accessed July 12, 2025, [https://juso-mental.com/blog/%E3%83%8A%E3%83%AB%E3%82%B3%E3%83%AC%E3%83%97%E3%82%B7%E3%83%BC%E3%80%81%E9%81%8E%E7%9C%A0%E7%97%87%E3%81%A7%E7%94%A8%E3%81%84%E3%82%89%E3%82%8C%E3%82%8B%E8%96%AC%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6](https://juso-mental.com/blog/%E3%83%8A%E3%83%AB%E3%82%B3%E3%83%AC%E3%83%97%E3%82%B7%E3%83%BC%E3%80%81%E9%81%8E%E7%9C%A0%E7%97%87%E3%81%A7%E7%94%A8%E3%81%84%E3%82%89%E3%82%8C%E3%82%8B%E8%96%AC%E3%81%AB%E3%81%A4%E3%81%84%E3%81%A6)  
12. Prevalence, incidence, and medications of narcolepsy in Japan: a descriptive observational study using a health insurance claims database, accessed July 12, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC10899966/](https://pmc.ncbi.nlm.nih.gov/articles/PMC10899966/)  
13. (PDF) Prevalence, incidence, and medications of narcolepsy in Japan: a descriptive observational study using a health insurance claims database \- ResearchGate, accessed July 12, 2025, [https://www.researchgate.net/publication/363120604\_Prevalence\_incidence\_and\_medications\_of\_narcolepsy\_in\_Japan\_a\_descriptive\_observational\_study\_using\_a\_health\_insurance\_claims\_database](https://www.researchgate.net/publication/363120604_Prevalence_incidence_and_medications_of_narcolepsy_in_Japan_a_descriptive_observational_study_using_a_health_insurance_claims_database)  
14. モディオダール錠 100 mg に関する資料, accessed July 12, 2025, [https://www.pmda.go.jp/drugs/2020/P20200218001/530258000\_21900AMZ00005\_B100\_1.pdf](https://www.pmda.go.jp/drugs/2020/P20200218001/530258000_21900AMZ00005_B100_1.pdf)  
15. Modiodal Tablets 100mg | Kusuri-no-Shiori(Drug Information Sheet), accessed July 12, 2025, [https://www.rad-ar.or.jp/siori/english/search/result?n=36200](https://www.rad-ar.or.jp/siori/english/search/result?n=36200)  
16. Importing or Bringing Medication into Japan for Personal Use, accessed July 12, 2025, [https://www.mhlw.go.jp/english/topics/import/index.html](https://www.mhlw.go.jp/english/topics/import/index.html)  
17. 9005 海外旅行者向け（医薬品・化粧品等）（カスタムスアンサー） \- 税関, accessed July 12, 2025, [https://www.customs.go.jp/tetsuzuki/c-answer/sonota/9005\_jr.htm](https://www.customs.go.jp/tetsuzuki/c-answer/sonota/9005_jr.htm)  
18. Import / Export Narcotics by carrying | NARCOTICS CONTROL DEPARTMENT, accessed July 12, 2025, [https://www.ncd.mhlw.go.jp/en/application2.html](https://www.ncd.mhlw.go.jp/en/application2.html)  
19. (別添)携帯による医療用麻薬等の輸入・輸出手続きに関する手引き, accessed July 12, 2025, [https://www.ncd.mhlw.go.jp/dl\_data/keitai/guide\_narcotics\_jp20241212.pdf](https://www.ncd.mhlw.go.jp/dl_data/keitai/guide_narcotics_jp20241212.pdf)  
20. I know all the requirements of bringing meds to Japan. But WHEN do I declare them?, accessed July 12, 2025, [https://www.reddit.com/r/JapanTravelTips/comments/177bhtx/i\_know\_all\_the\_requirements\_of\_bringing\_meds\_to/](https://www.reddit.com/r/JapanTravelTips/comments/177bhtx/i_know_all_the_requirements_of_bringing_meds_to/)  
21. Prescription Medication Import : r/JapanTravelTips \- Reddit, accessed July 12, 2025, [https://www.reddit.com/r/JapanTravelTips/comments/1l13shm/prescription\_medication\_import/](https://www.reddit.com/r/JapanTravelTips/comments/1l13shm/prescription_medication_import/)  
22. 海外渡航先への医薬品の携帯による持ち込み・持ち出しの手続きについて \- 厚生労働省, accessed July 12, 2025, [https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou\_iryou/iyakuhin/yakubuturanyou/index\_00005.html](https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iyakuhin/yakubuturanyou/index_00005.html)  
23. 医薬品等の個人輸入について | あやしいヤクブツ連絡ネット \- 厚生労働省, accessed July 12, 2025, [https://www.yakubutsu.mhlw.go.jp/individualimport/purchase/](https://www.yakubutsu.mhlw.go.jp/individualimport/purchase/)  
24. BRINGING MEDICATIONS FOR PERSONAL USE INTO JAPAN \- FEI, accessed July 12, 2025, [https://inside.fei.org/system/files/Bringing%20medication%20for%20personal%20use%20into%20Japan%2016July2021.pdf](https://inside.fei.org/system/files/Bringing%20medication%20for%20personal%20use%20into%20Japan%2016July2021.pdf)  
25. 【個人向け】麻薬・覚醒剤原料などを携帯して日本を出入国する方へ, accessed July 12, 2025, [https://www.ncd.mhlw.go.jp/shinsei6.html](https://www.ncd.mhlw.go.jp/shinsei6.html)  
26. Information for those who are bringing medicines for personal use into Japan, accessed July 12, 2025, [https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/01.html](https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/01.html)  
27. Bringing Medications into Japan | Embassy of Japan in the United States of America, accessed July 12, 2025, [https://www.us.emb-japan.go.jp/itpr\_en/bringing-medications-to-japan.html](https://www.us.emb-japan.go.jp/itpr_en/bringing-medications-to-japan.html)  
28. Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices \- Wikipedia, accessed July 11, 2025, [https://en.wikipedia.org/wiki/Act\_on\_Securing\_Quality,\_Efficacy\_and\_Safety\_of\_Products\_Including\_Pharmaceuticals\_and\_Medical\_Devices](https://en.wikipedia.org/wiki/Act_on_Securing_Quality,_Efficacy_and_Safety_of_Products_Including_Pharmaceuticals_and_Medical_Devices)  
29. Outline of the Law for Partial Revision of the Pharmaceutical Affairs Law, accessed July 11, 2025, [https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/dl/150407-01.pdf](https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/dl/150407-01.pdf)  
30. What is the 'Japanese Pharmaceutical and Medical Device Act (Formerly the Japanese Pharmaceutical Affairs Law)'? Explaining its Purpose, Regulatory Targets, and Advertising Regulations | MONOLITH LAW OFFICE | Tokyo, Japan, accessed July 11, 2025, [https://monolith.law/en/general-corporate/pharmaceuticals-law](https://monolith.law/en/general-corporate/pharmaceuticals-law)  
31. Act on Securing Quality, Efficacy and Safety of Products Including ..., accessed July 11, 2025, [https://www.japaneselawtranslation.go.jp/en/laws/view/3213](https://www.japaneselawtranslation.go.jp/en/laws/view/3213)  
32. The Law on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical devices (Tentative translatio, accessed July 11, 2025, [https://faolex.fao.org/docs/pdf/jap178782original.pdf](https://faolex.fao.org/docs/pdf/jap178782original.pdf)  
33. An Overview of Pharmaceutical and Medical Device Regulation in Japan \- Morgan Lewis, accessed July 11, 2025, [https://www.morganlewis.com/-/media/files/publication/outside-publication/article/overview\_pharma\_device\_reg.ashx](https://www.morganlewis.com/-/media/files/publication/outside-publication/article/overview_pharma_device_reg.ashx)  
34. CHAPTER 2.PHARMACEUTICAL LAWS AND REGULATIONS, accessed July 11, 2025, [https://www.jpma.or.jp/english/about/parj/eki4g6000000784o-att/2020e\_ch02.pdf](https://www.jpma.or.jp/english/about/parj/eki4g6000000784o-att/2020e_ch02.pdf)  
35. Narcotics and Psychotropics Control Law \- Wikipedia, accessed July 11, 2025, [https://en.wikipedia.org/wiki/Narcotics\_and\_Psychotropics\_Control\_Law](https://en.wikipedia.org/wiki/Narcotics_and_Psychotropics_Control_Law)  
36. LAWS AND REGULATIONS \- United Nations Digital Library System, accessed July 11, 2025, [https://digitallibrary.un.org/record/201311/files/e-nl-1994-38-e.pdf](https://digitallibrary.un.org/record/201311/files/e-nl-1994-38-e.pdf)  
37. Special Feature Article The Roles and Problems of the Narcotics Addict Reporting System Toshihiko MATSUMOTO Department of Drug D, accessed July 11, 2025, [https://www.jspn.or.jp/uploads/uploads/files/english/122-8\_P602-609\_Toshihiko\_MATSUMOTO.pdf](https://www.jspn.or.jp/uploads/uploads/files/english/122-8_P602-609_Toshihiko_MATSUMOTO.pdf)  
38. 病院・診療所における向精神薬取扱いの手引 \- 厚生労働省, accessed July 12, 2025, [https://www.mhlw.go.jp/bunya/iyakuhin/yakubuturanyou/dl/kouseishinyaku\_01.pdf](https://www.mhlw.go.jp/bunya/iyakuhin/yakubuturanyou/dl/kouseishinyaku_01.pdf)  
39. 薬局における向精神薬取扱いの手引き \- 広島県, accessed July 12, 2025, [https://www.pref.hiroshima.lg.jp/uploaded/life/965364\_8757236\_misc.pdf](https://www.pref.hiroshima.lg.jp/uploaded/life/965364_8757236_misc.pdf)  
40. 9005 For Overseas Travelers (Quasi-drugs/ Cosmetics, etc. ) : Japan Customs, accessed July 11, 2025, [https://www.customs.go.jp/english/c-answer\_e/sonota/9005\_e.htm](https://www.customs.go.jp/english/c-answer_e/sonota/9005_e.htm)  
41. Importing or Bringing Medication into Japan for Personal Use, accessed July 12, 2025, [https://www.mhlw.go.jp/www1/english/importing/e0813-1.html](https://www.mhlw.go.jp/www1/english/importing/e0813-1.html)  
42. Frequently Asked Questions (FAQ) | Pharmaceuticals and Medical Devices Agency, accessed July 11, 2025, [https://www.pmda.go.jp/english/about-pmda/0004.html](https://www.pmda.go.jp/english/about-pmda/0004.html)  
43. Regulations and Approval/Certification of Medical Devices, accessed July 11, 2025, [https://www.pmda.go.jp/english/review-services/reviews/0004.html](https://www.pmda.go.jp/english/review-services/reviews/0004.html)  
44. Cannabis in Japan \- Wikipedia, accessed July 12, 2025, [https://en.wikipedia.org/wiki/Cannabis\_in\_Japan](https://en.wikipedia.org/wiki/Cannabis_in_Japan)  
45. Medical Cannabis & Cannabinoid Regulation 2023, accessed July 12, 2025, [https://www.morihamada.com/system/files/publications/publications/pdf/Chambers%20Global%20Practice%20Guides%20Medical%20Cannabis%20and%20Cannabinoid%20Regulation%202023%20-%20Japan%20Trends%20and%20Developments.pdf](https://www.morihamada.com/system/files/publications/publications/pdf/Chambers%20Global%20Practice%20Guides%20Medical%20Cannabis%20and%20Cannabinoid%20Regulation%202023%20-%20Japan%20Trends%20and%20Developments.pdf)  
46. Cannabis Control Act \- English \- Japanese Law Translation, accessed July 12, 2025, [https://www.japaneselawtranslation.go.jp/en/laws/view/2594/en](https://www.japaneselawtranslation.go.jp/en/laws/view/2594/en)  
47. 18\. Cannabis Control Act : Tokyo Customs, accessed July 12, 2025, [http://www.customs.go.jp/tokyo/english/yuubin/taimatorishimari.htm](http://www.customs.go.jp/tokyo/english/yuubin/taimatorishimari.htm)  
48. CBDを含有する製品について｜麻薬取締部ウェブサイト \- 厚生労働省, accessed July 12, 2025, [https://www.ncd.mhlw.go.jp/cbd.html](https://www.ncd.mhlw.go.jp/cbd.html)  
49. Cannabis-Derived Drugs in Japan: New Legislation and Outlook \- PharmaBoardroom, accessed July 12, 2025, [https://pharmaboardroom.com/articles/cannabis-derived-drugs-in-japan-new-legislation-and-outlook/](https://pharmaboardroom.com/articles/cannabis-derived-drugs-in-japan-new-legislation-and-outlook/)  
50. 2024年に日本のCBD規制はどう変わる？大麻取締法改正でおさえるべきポイント \- DR.VAPE, accessed July 12, 2025, [https://drvape.jp/shop/pages/column\_2412\_cbd](https://drvape.jp/shop/pages/column_2412_cbd)  
51. 日本のCBD規制を徹底解説！大麻取締法改正でおさえるべきポイントとは？, accessed July 12, 2025, [https://www.hempassist.jp/view/page/blog-what-cbd-regulations](https://www.hempassist.jp/view/page/blog-what-cbd-regulations)  
52. How Has Japan's Cannabis Control Act Been Amended? \- PubMed, accessed July 12, 2025, [https://pubmed.ncbi.nlm.nih.gov/40489340/](https://pubmed.ncbi.nlm.nih.gov/40489340/)  
53. Japan's Cannabis Law Reforms:, accessed July 12, 2025, [https://grjapan.com/sites/default/files/content/articles/files/20241017%20GR%20Japan%20Industry%20Insight%20Amended%20CCA.pdf](https://grjapan.com/sites/default/files/content/articles/files/20241017%20GR%20Japan%20Industry%20Insight%20Amended%20CCA.pdf)  
54. Can you bring CBD to Japan? Importing process and standards \- Essentia Pura, accessed July 12, 2025, [https://essentiapura.com/importing-cbd-into-japan/](https://essentiapura.com/importing-cbd-into-japan/)  
55. The Evolution of Japan's Cannabis Market in 2024 and the Impact of Legal Regulations, accessed July 12, 2025, [https://www.euromonitor.com/article/the-evolution-of-japans-cannabis-market-in-2024-and-the-impact-of-legal-regulations](https://www.euromonitor.com/article/the-evolution-of-japans-cannabis-market-in-2024-and-the-impact-of-legal-regulations)  
56. Japan Issues Update on New THC Limits in CBD Products Which Remain 'Strictest in the World' \- Business of Cannabis, accessed July 12, 2025, [https://businessofcannabis.com/japan-issues-update-on-new-thc-limits-in-cbd-products-which-remain-strictest-in-the-world/](https://businessofcannabis.com/japan-issues-update-on-new-thc-limits-in-cbd-products-which-remain-strictest-in-the-world/)  
57. Japan Issues New Guidance on THC Limits in CBD Products, accessed July 12, 2025, [https://cbd.market/news/japan-issues-new-thc-limits-in-cbd-products](https://cbd.market/news/japan-issues-new-thc-limits-in-cbd-products)  
58. Cannabis-Derived Drugs in Japan: New Legislation and Outlook \- DIA Global Forum, accessed July 12, 2025, [https://globalforum.diaglobal.org/issue/february-2025/cannabis-derived-drugs-in-japan-new-legislation-and-outlook/](https://globalforum.diaglobal.org/issue/february-2025/cannabis-derived-drugs-in-japan-new-legislation-and-outlook/)  
59. 日本で医薬品としてCBD使用が可能に – 改正大麻取締法が可決 \- HealthyTOKYO, accessed July 12, 2025, [https://healthytokyo.com/ja/blog/cbd-use-as-medicine-now-possible-in-japan/](https://healthytokyo.com/ja/blog/cbd-use-as-medicine-now-possible-in-japan/)  
60. コンサータは市販されてる？買えない理由と処方薬の入手方法・危険性, accessed July 12, 2025, [https://mencli.ashitano.clinic/34589](https://mencli.ashitano.clinic/34589)  
61. miusa.org, accessed July 12, 2025, [https://miusa.org/resource/tip-sheets/japanfocus/\#:\~:text=Identify%20if%20Your%20Medication%20is%20Controlled\&text=You%20will%20have%20to%20check,Control%20Department%20to%20bring%20it.](https://miusa.org/resource/tip-sheets/japanfocus/#:~:text=Identify%20if%20Your%20Medication%20is%20Controlled&text=You%20will%20have%20to%20check,Control%20Department%20to%20bring%20it.)  
62. Japan Focus: ADHD and Traveling with Medication \- MIUSA, accessed July 12, 2025, [https://miusa.org/resource/tip-sheets/japanfocus/](https://miusa.org/resource/tip-sheets/japanfocus/)  
63. Aculys Pharma Announces Positive Results in Japan Phase III Clinical Trial of Pitolisant in Patients with Obstructive Sleep Apnea Syndrome (OSAS) \- Catalys Pacific, accessed July 12, 2025, [https://catalyspacific.com/perspective/aculys-pharma-announces-positive-results-in-japan-phase-iii-clinical-trial-of-pitolisant-in-patients-with-obstructive-sleep-apnea-syndrome-osas](https://catalyspacific.com/perspective/aculys-pharma-announces-positive-results-in-japan-phase-iii-clinical-trial-of-pitolisant-in-patients-with-obstructive-sleep-apnea-syndrome-osas)  
64. Up all night to make a new drug for narcolepsy | Drug Discovery News, accessed July 12, 2025, [https://www.drugdiscoverynews.com/up-all-night-to-make-a-new-drug-for-narcolepsy-16152](https://www.drugdiscoverynews.com/up-all-night-to-make-a-new-drug-for-narcolepsy-16152)  
65. ナルコレプシーに有効な薬と生活サイクルの改善 \- メディカルノート, accessed July 12, 2025, [https://medicalnote.jp/diseases/%E3%83%8A%E3%83%AB%E3%82%B3%E3%83%AC%E3%83%97%E3%82%B7%E3%83%BC/contents/160223-007-UD](https://medicalnote.jp/diseases/%E3%83%8A%E3%83%AB%E3%82%B3%E3%83%AC%E3%83%97%E3%82%B7%E3%83%BC/contents/160223-007-UD)  
66. Modafinil \- StatPearls \- NCBI Bookshelf, accessed July 12, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK531476/](https://www.ncbi.nlm.nih.gov/books/NBK531476/)  
67. ＰＤＦ \- 医薬品インタビューフォーム, accessed July 12, 2025, [https://pins.japic.or.jp/pdf/medical\_interview/IF00006381.pdf](https://pins.japic.or.jp/pdf/medical_interview/IF00006381.pdf)  
68. Modafinil \- Wikipedia, accessed July 12, 2025, [https://en.wikipedia.org/wiki/Modafinil](https://en.wikipedia.org/wiki/Modafinil)  
69. Narcolepsy: current treatment options and future approaches \- PMC \- PubMed Central, accessed July 12, 2025, [https://pmc.ncbi.nlm.nih.gov/articles/PMC2526380/](https://pmc.ncbi.nlm.nih.gov/articles/PMC2526380/)  
70. なるこ会 ＮＰＯ法人日本ナルコレプシー協会, accessed July 12, 2025, [https://narukokai.or.jp/qa.html](https://narukokai.or.jp/qa.html)  
71. ADHD治療薬の処方を希望される方へ \- 三鷹駅こころえがおクリニック, accessed July 12, 2025, [https://kokoro-egao.net/prescription.html](https://kokoro-egao.net/prescription.html)  
72. Controlled Substances List, accessed July 12, 2025, [https://www.ncd.mhlw.go.jp/dl\_data/keitai/cotrolled\_substances\_list20241212%20.pdf](https://www.ncd.mhlw.go.jp/dl_data/keitai/cotrolled_substances_list20241212%20.pdf)  
73. Bringing Medications into Japan – AKP | Study Abroad in Kyoto \- Associated Kyoto Program, accessed July 12, 2025, [https://www.associatedkyotoprogram.org/bringing-medications-japan/](https://www.associatedkyotoprogram.org/bringing-medications-japan/)  
74. Medical Information, accessed July 12, 2025, [https://japan.embassy.gov.au/tkyo/medical.html](https://japan.embassy.gov.au/tkyo/medical.html)  
75. CAN YOU TAKE ADHD MEDICATION TO JAPAN? \- The Tokyo Chapter, accessed July 12, 2025, [https://www.thetokyochapter.com/can-you-take-adhd-medication-to-japan/](https://www.thetokyochapter.com/can-you-take-adhd-medication-to-japan/)  
76. Importing Medication To Japan \- Interac Network, accessed July 12, 2025, [https://interacnetwork.com/importing-medication-to-japan/](https://interacnetwork.com/importing-medication-to-japan/)  
77. モダフィニル \- PMDA, accessed July 12, 2025, [https://www.pmda.go.jp/drugs/2007/P200700011/530258000\_21900AMZ00005\_B100\_3.pdf](https://www.pmda.go.jp/drugs/2007/P200700011/530258000_21900AMZ00005_B100_3.pdf)